Introduction: Genetic resistance pathways including primary mutations at codons Y143C/H/R, Q148H/K/R or N155H together with one or more additional associated secondary mutations at L74M, E92Q, T97A, E138E/A/K or G140S/A, has been reported to result in higher levels of resistance with RAL treatment.
Table: N155H
Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen.
Evidence for Disruption of Mg(2+) Pair as a Resistance Mechanism Against HIV-1 Integrase Strand Transfer Inhibitors.
PMID: 32974383
2020
Frontiers in molecular biosciences
Abstract: In the present study, we use molecular dynamics simulations to understand the impact of the N155H mutation in the HIV-1 integrase structure and dynamics, when alone or in combination with Q148H.
Abstract: Moreover, mutation N155H and the resistance-related mutation Q148H are mutually exclusive for unknown reasons.
Abstract: While some resistance-related mutations occur near the inhibitor's binding site, the mutation N155H occurs on the opposite side of the drug-interacting Mg2+ ions, thus, not interacting directly with the drug molecules and currently lacking an explanation for its resistance mechanism.
Introduction: Here, we use information from the cryo-EM STC structure of the HIV-1 IN to build models of cSSC of the wi
Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
PMID: 32853364
2020
The Journal of antimicrobial chemotherapy
Abstract: HIV integrase-recombinant virus carrying one primary INSTI DRM (N155H or Y143R/S) was susceptible to dolutegravir but highly resistant to raltegravir and elvitegravir (>50-fold change).
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
PMID: 32675772
2020
Journal of acquired immune deficiency syndromes (1999)
Discussion: Interestingly, in 1 participant with baseline integrase substitutions N155N/H and G163G/R by proviral DNA genotype assay, only the integrase polymorphism mixture (V151V/I), which is not associated with dolutegravir resistance, was detected at virologic failure.
Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting.
Result: Among patients with M184V mutation, two had mutations at position 138 of reverse transcriptase that is associated with low-level resistance to the
Discussion: G118R, Y143C, and N155H were the main pathways to virologic failure.
Discussion: G118R, Y143C, and N155H were the major integrase mutations accounting for the virologic failure detected in three out of seven patients, following 32 to 48 weeks of RAL-based regimen.
Discussion: N155H was the main mutation pathway for virologic failure, followed by Q143R and Q148R/H mutation pathways.
Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
Discussion: N155H, Q148H/R/K, and Y143R/C/H are the three major recognized pathways of genotypic resistance against InSTIs.
Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
PMID: 32450199
2020
International journal of antimicrobial agents
Abstract: The primary INSTI resistance substitutions E138A/K, G140S, Y143C/H/R, Q148H and N155H were detected in 14 of 22 samples and were associated with resistance to one or more INSTIs, with G140S+Q148H present in 11 of 22 samples.
Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance.
PMID: 30648124
2019
Open forum infectious diseases
Introduction: DTG appears to have a high genetic barrier to resistance, unlike the other drugs within the INSTI class, raltegravir and elvitegravir, which select for major resistance mutations such as N155H, Y143H/R/C, G140A/S, and Q148H/R/K.
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
HIV mutation literature information.
PMID: 
2020
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT